Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025

Same author

First description of endoscopic dilation of stricturing Kono-S anastomosis in Crohn's disease.

Techniques in coloproctology·2025

Same author

Post-operative morbidity in Crohn's disease: what is the impact of patient-, disease- and surgery-related factors?

International journal of colorectal disease·2022

Same author

Crohn's disease and Takayasu's arteritis: are they associated?

European review for medical and pharmacological sciences·2021

Same author

Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial.

European review for medical and pharmacological sciences·2020

Same author

Preventing recurrence in Crohn's disease: the Kono-S anastomosis with two-layer technique.

Techniques in coloproctology·2020

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Cancer immunotherapy, mathematical modeling and optimal control.

F Castiglione¹, B Piccoli

¹Istituto Applicazioni del Calcolo (IAC) "M. Picone", Consiglio Nazionale delle Ricerche (CNR), Viale del Policlinico 137, 00161 Rome, Italy. f.castiglione@iac.cnr.it

Journal of Theoretical Biology

|June 5, 2007

Summary

This study introduces a mathematical model to optimize cancer immunotherapy by determining the ideal timing and dosage of therapeutic agents. This approach ensures a prolonged and effective immune response against cancer for better patient outcomes.

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

Related Experiment Videos

Last Updated: Jul 14, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

Area of Science:

Immunology
Mathematical Biology
Computational Science

Background:

Clinical immunologists seek optimal timing and dosage for therapeutic agents to manage pathological conditions.
Cancer immunotherapies involve agents that elicit immune responses against cancer, with dynamics influenced by immunogenicity and duration.
A key challenge is determining optimal administration schedules for prolonged and effective anti-cancer immune responses.

Purpose of the Study:

To develop a mathematical framework for optimizing cancer immunotherapy protocols.
To apply optimal control theory to determine precise dosing and timing strategies for immunotherapeutic agents.
To provide a method for enhancing the effectiveness of cancer treatments through calculated immune system stimulation.

Main Methods:

Constructing a mathematical model of cancer-immune system interactions.
Applying optimal control theory to a system of ordinary differential equations describing the dynamics.
Determining discrete, variable doses and administration times for immunotherapeutic agents within a therapeutic period.

Main Results:

A method is presented to solve the mathematical problem of optimizing immunotherapy administration.
The approach allows for the calculation of optimal protocols for cancer treatment.
Demonstrates the applicability of the method across various clinical scenarios.

Conclusions:

The developed mathematical model and optimal control strategy offer a systematic approach to personalize cancer immunotherapy.
This method can guide clinical decisions on when and how much immunotherapeutic agent to administer.
The framework is adaptable to other clinical problems described by ordinary differential equations involving treatment kinetics and physiological functions.